2,2',2''-(10-(2-((4-((5R,8S,11S,14S,17S,20S,23R)-23-((S)-2-((2S,3R)-2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-3-hydroxy-N-methylbutanamido)-4,4-dimethylpentanamido)-17-(2-amino-2-oxoethyl)-5-(((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamoyl)-8-(carboxymethyl)-20-((1-(carboxymethyl)piperidin-4-yl)methyl)-14-(naphthalen-2-ylmethyl)-7,10,13,16,19,22-hexaoxo-1,3-dithia-6,9,12,15,18,21-hexaazacyclotetracosan-11-yl)butyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid

Catalog No. :
ACYFQX023
CAS No. :
3066864-32-9
Molecular Formula :
C101H140N22O26S2
Molecular Weight :
2142.49

IUPAC Name:2,2',2''-(10-(2-((4-((5R,8S,11S,14S,17S,20S,23R)-23-((S)-2-((2S,3R)-2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-3-hydroxy-N-methylbutanamido)-4,4-dimethylpentanamido)-17-(2-amino-2-oxoethyl)-5-(((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamoyl)-8-(carboxymethyl)-20-((1-(carboxymethyl)piperidin-4-yl)methyl)-14-(naphthalen-2-ylmethyl)-7,10,13,16,19,22-hexaoxo-1,3-dithia-6,9,12,15,18,21-hexaazacyclotetracosan-11-yl)butyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid

2,2',2''-(10-(2-((4-((5R,8S,11S,14S,17S,20S,23R)-23-((S)-2-((2S,3R)-2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-3-hydroxy-N-methylbutanamido)-4,4-dimethylpentanamido)-17-(2-amino-2-oxoethyl)-5-(((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamoyl)-8-(carboxymethyl)-20-((1-(carboxymethyl)piperidin-4-yl)methyl)-14-(naphthalen-2-ylmethyl)-7,10,13,16,19,22-hexaoxo-1,3-dithia-6,9,12,15,18,21-hexaazacyclotetracosan-11-yl)butyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2,2',2''-(10-(2-((4-((5R,8S,11S,14S,17S,20S,23R)-23-((S)-2-((2S,3R)-2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-3-hydroxy-N-methylbutanamido)-4,4-dimethylpentanamido)-17-(2-amino-2-oxoethyl)-5-(((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamoyl)-8-(carboxymethyl)-20-((1-(carboxymethyl)piperidin-4-yl)methyl)-14-(naphthalen-2-ylmethyl)-7,10,13,16,19,22-hexaoxo-1,3-dithia-6,9,12,15,18,21-hexaazacyclotetracosan-11-yl)butyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid
IUPAC Name2,2',2''-(10-(2-((4-((5R,8S,11S,14S,17S,20S,23R)-23-((S)-2-((2S,3R)-2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-3-hydroxy-N-methylbutanamido)-4,4-dimethylpentanamido)-17-(2-amino-2-oxoethyl)-5-(((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamoyl)-8-(carboxymethyl)-20-((1-(carboxymethyl)piperidin-4-yl)methyl)-14-(naphthalen-2-ylmethyl)-7,10,13,16,19,22-hexaoxo-1,3-dithia-6,9,12,15,18,21-hexaazacyclotetracosan-11-yl)butyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid
Molecular FormulaC101H140N22O26S2
Molecular Weight2142.49
SMILESO=C(N1[C@@H](CCC1)C(N)=O)[C@@H](NC([C@H]2NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CSCSC2)NC([C@H](CC(C)(C)C)N(C)C([C@H]([C@H](O)C)NC([C@@H](NC(C)=O)CC3=CNC4=CC=CC=C34)=O)=O)=O)=O)CC5CCN(CC5)CC(O)=O)=O)CC(N)=O)=O)CC6=CC7=C(C=CC=C7)C=C6)=O)CCCCNC(CN8CCN(CCN(CCN(CC8)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)CC(O)=O)=O)=O)CC9=CNC%10=CC=CC=C9%10
InChI KeyYBIHAYCVELUNPG-IZEHOFEZSA-N
CAS No.3066864-32-9

Synthetic Route by SureRoute

1. ACYFQX023 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACYFQX023 route product structure diagram
    ACYFQX0233066864-32-9
Inquiry

2. ACYFQX023 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACYFQX023 route product structure diagram
    ACYFQX0233066864-32-9
Inquiry

Comments (0)